Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- cholera vaccine, live
- vaccinia immune globulin
Interactions between your drugs
vaccinia immune globulin cholera vaccine, live
Applies to: vaccinia immune globulin, cholera vaccine, live
ADJUST DOSING INTERVAL: Administration of vaccinia immune globulin intravenous, human (VIGIV) with, or shortly before, or shortly after live viral vaccines may impair the immune response to the vaccination(s). Injected live, attenuated virus vaccines, particularly measles/mumps/rubella (MMR), measles/mumps/rubella/varicella (MMRV), or monovalent varicella, may be affected by circulating antibodies present in VIGIV. The passive transfer of these antibodies may prevent replication of the vaccine virus, potentially reducing the vaccine's efficacy. In general, there appears to be minimal to no interaction between immune globulin (Ig) preparations or blood products and the yellow fever vaccine, some live oral vaccines (e.g., rotavirus, typhoid), the live attenuated influenza vaccine (LAIV), and the Bacille Calmette-Guerin (BCG) vaccine. As this interaction is dependent upon the antibodies present in VIGIV, it may be affected by the source used to develop the VIGIV product. Additionally, the vaccinations impacted may vary from country to country. Data on the immunogenicity and safety of all vaccinations (e.g., dengue vaccine) given concurrently with or shortly before or after the administration of VIGIV are not available.
MANAGEMENT: Immunization with live virus vaccines should be deferred until approximately 3 months after the administration of VIGIV. People who received VIGIV shortly after live virus vaccination should be revaccinated 3 months after the administration of the Ig. In general, most immunization guidelines indicate that live virus vaccines can be safely administered 2 to 3 weeks prior to Ig products. Local immunization guidelines and prescribing information for the specific products involved should be consulted for further recommendations.
References (13)
- (1993) "Interference of immune globulin with measles and rubella immunization." Eur J Pediatr, 152, p. 536
- CDC. Centers for Disease Control and Prevention/ (1993) "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep, 42(RR-04), p. 1-18
- Department of Health. National Health Service (2019) Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf
- (2023) "Product Information. Vaxchora (cholera vaccine, live)." Patientric Ltd
- (2024) "Product Information. Vaxchora (cholera vaccine, live)." Emergent Travel Health, Inc
- Advisory Committee on Immunization Practices: Centers for Disease Control and Prevention General Best Practice Guidelines for Immunization: Timing and Spacing of Immunobiologics https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html
- Clucas L, Crawford N, Danchin M, Greenway A Live-attenuated vaccines in patients receiving regular red blood cell transfusions https://mvec.mcri.edu.au/references/live-attenuated-vaccines-in-patients-receiving-regular-red-blood-cell-transfusions/
- Melbourne Vaccine Education Centre Live-attenuated vaccines and immunoglobulins or blood products https://mvec.mcri.edu.au/references/live-attenuated-vaccines-and-immunoglobulins-or-blood-products/
- Australian Government. Department of Health and Aged Care Australian Immunisation Handbook: Vaccination for people who have recently received normal human immunoglobulin and other blood products https://immunisationhandbook.health.gov.au/contents/vaccination-for-special-risk-groups/vaccination-for-people-who-ha
- Australian Government. Department of Health and Aged Care Australian Immunisation Handbook: Tuberculosis https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/tuberculosis
- Australian Government. Department of Health and Aged Care Australian Immunisation Handbook: Varicella (chickenpox) https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/varicella-chickenpox
- Emergent BioSolutions Canada Inc. (2025) CNJ-016- vaccinia immune globulin (human) injection https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a4f9f620-e6e4-4a03-a9a7-79007c8c2cfe&type=display#i4i_section_id_267c1983-0609-4608-b6ed-f3415cebe5d1
- Emergent BioSolutions Canada Inc. (2025) Product monograph including patient medication information. CNJ-016(TM). Vaccinia Immunoglobulin Intravenous (human) [VIGIV]. https://pdf.hres.ca/dpd_pm/00046385.PDF
Drug and food interactions
cholera vaccine, live food
Applies to: cholera vaccine, live
ADJUST DOSING INTERVAL: Coadministration of oral cholera vaccine with food or an oral beverage may impair its efficacy. The formulations of both the inactivated and live, attenuated oral cholera vaccines (Dukoral and Vaxchora, respectively) are acid-labile, and must be administered with a buffer. According to the manufacturer, eating and drinking may interfere with the protective effect of the buffer. However, clinical data are not available.
MANAGEMENT: It is recommended that patients avoid eating or drinking for 60 minutes before and after administration of either Dukoral or Vaxchora oral cholera vaccines.
References (4)
- (2023) "Product Information. Vaxchora (cholera vaccine, live)." Patientric Ltd
- (2022) "Product Information. Dukoral (cholera vaccine, inactivated)." Valneva Sweden AB
- (2023) "Product Information. Dukoral (cholera vaccine)." Valneva UK Ltd
- (2024) "Product Information. Vaxchora (cholera vaccine, live)." Emergent Travel Health, Inc
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Bexsero
Bexsero is used for meningitis, meningococcal, meningococcal disease prophylaxis
Biothrax
BioThrax is used to help prevent anthrax in people exposed to the bacteria through the skin or ...
Capvaxive
Capvaxive (pneumococcal 21-valent conjugate vaccine) is a single-dose vaccine that may be used to ...
Cyfendus
Cyfendus (anthrax vaccine adsorbed, adjuvanted) is a vaccine indicated for the post-exposure ...
Hiberix
Hiberix vaccine is used to prevent infection caused by haemophilus B bacteria. Learn about side ...
Liquid PedvaxHIB
Liquid PedvaxHIB is used for haemophilus influenzae prophylaxis
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.